Twice-Daily Administration of a Long-Acting Angiotensin-Converting Enzyme Inhibitor Has Greater Effects on Neurohumoral Factors than a Once-Daily Regimen in Patients with Chronic Congestive Heart Failure

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 1, 2004, Pages 56-60

  Hirooka, Keiji ^a   Koretsune, Yukihiro ^a   Yoshimoto, Sachiko ^a   Irino, Hiroaki ^a   Abe, Haruhiko ^a   Yasuoka, Yoshinori ^a   Yamamoto, Hiroyoshi ^a   Hashimoto, Katsuji ^a   Chin, Wakatomi ^a   Kusuoka, Hideo ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Heart failure; Neurohumoral factor; Renin angiotensin aldosterone system; Twice daily regimen

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; NEUROHORMONE;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RR INTERVAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIURETICS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; LISINOPRIL; MALE; NOREPINEPHRINE; RENIN-ANGIOTENSIN SYSTEM;

EID: 9144254602     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200401000-00009     Document Type: Article

References (20)

1. Chatterjee K, Parmley WW. Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure. J Am Coll Cardiol. 1983;1:133-153.
2. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984;101:370-377.
3. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation. 1987;75(5 Pt 2): IV36-48.
4. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
5. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
6. Agostoni PG, De Cesare N, Doria E, et al. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J. 1986;55:391-399.
7. Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2001;38:2101-2113.
8. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997;18:736-753.
9. Packer M, Lee WH, Kessler PD, et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987;75(5 Pt 2): IV80-92.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
11. The CONSENSUS Trial Study Group. Effects ofenalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
12. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
13. Francis GS, Rucinska EJ. Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure. Am J Cardiol. 1989;63:17D-21D.
14. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
16. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 1998;32(suppl 1):S22-S30.
17. Gilbert EM, Sandoval A, Larrabee P, et al. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation. 1993;88:472-480.
18. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32:1811-1818.
19. Stone CK, Uretsky BF, Linnemeier TJ, et al. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol. 1989;63:567-570.
20. Uretsky BF, Shaver JA, Liang CS, et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J. 1988;116:480-488.